🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
In this phase II trial, the investigators overarching goal is to demonstrat...
Status
Recruiting
Location
University of Washington
Start Date
2022-11-27
Trial ID
NCT05340465
Treatments Being Tested
The main purpose of this study is to see if pegfilgrastim (Neulasta) is saf...
Status
Completed
Location
Massachusetts General Hospital
Start Date
2003-07
Trial ID
NCT00146562
Treatments Being Tested
The primary objective was to assess the superiority of darbepoetin alfa ver...
Status
Completed
Location
Research Site
Start Date
2011-12-21
Trial ID
NCT01362140
Treatments Being Tested
This study will assess the efficacy and safety of methoxy polyethylene glyc...
Status
Terminated
Location
Multiple Locations
Start Date
2007-04
Trial ID
NCT00454246
Treatments Being Tested
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered...
Status
Completed
Location
Multiple Locations
Start Date
2006-12
Trial ID
NCT00401544
Treatments Being Tested
This study is a multi-institution, open-label, Phase 1b/2 clinical trial ev...
Status
Active Not Recruiting
Location
Moffitt Cancer Center
Start Date
2021-03-30
Trial ID
NCT04798339
Treatments Being Tested
This study will assess the comfort of subcutaneous injections of NeoRecormo...
Status
Completed
Location
Multiple Locations
Start Date
2006-09
Trial ID
NCT00377481
Treatments Being Tested
The purpose of this study is to determine the impact of erythropoietin trea...
Status
Withdrawn
Location
CHU Henri Mondor
Start Date
2008-11
Trial ID
NCT00579046
Treatments Being Tested
This study was conducted to explore a new therapy for anemia in participant...
Status
Completed
Location
Site BE32004
Start Date
2014-11-21
Trial ID
NCT02278341
Treatments Being Tested
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritum...
Status
Completed
Location
Memorial Sloan Kettering Cancer Center
Start Date
2003-02-10
Trial ID
NCT00058422